Our mission is to improve medical treatment for patients with immunologic and inflammatory diseases.
- Lead clinical candidate: atacicept, a novel biologic inhibitor of B cells and plasma cells, the cells that can produce disease causing antibodies.
- In clinical trials for IgA nephropathy (IgAN), an autoimmune disease that leads to kidney failure.
- No disease-modifying medication currently available.
- Target profile: self-administered subcutaneously once per week.